Sanity Group
Berlin-based cannabis operator focused on the German medical market, the CBD brand Vaay, and Swiss pilot trials.
Sanity Group is one of the more visible German cannabis operators, but most of what you'll read about it comes from press releases and trade press, not independent audits. The frequently quoted '10% of the German medical market' figure is a company claim that's hard to verify externally. Treat market share, revenue, and patient-count numbers as self-reported. The Organigram minority stake and the Vaay CBD brand are well-documented; the rest deserves skepticism.
What it is
Sanity Group GmbH is a German cannabis company headquartered in Berlin, founded in 2018 by Finn Age Hänsel and Fabian Friede [1][2]. It operates across two broad areas: medical cannabis (distribution to German pharmacies and clinical research partnerships) and consumer CBD products, primarily under the Vaay brand [1][3]. The company also has activities in the Swiss adult-use pilot trials that began in the mid-2020s [4].
Unlike vertically integrated North American licensed producers, Sanity Group's structure is closer to a distributor-plus-brand-house: it sources cultivated flower from licensed producers and focuses on importation, GMP-compliant handling, pharmacy supply, and brand building rather than running its own large-scale cultivation.
Ownership and structure
Sanity Group has raised multiple funding rounds from a mix of strategic and financial investors. The Canadian licensed producer Organigram Holdings disclosed a minority equity investment in Sanity Group in 2021 [5]. Other reported investors over time have included Casa Verde Capital (the venture fund associated with Snoop Dogg), Redalpine, and various German family offices [2][3].
Organigram's stake is a minority position; Sanity Group is not a subsidiary of Organigram and continues to operate independently with its own management. Exact cap-table percentages are not fully public, and readers should treat any specific ownership-percentage claims with caution unless sourced from a current Organigram filing [5].
Market and category focus
The company's core market is Germany, which moved from a narrow medical-only framework to a broader model under the 2024 Cannabis Act (CanG), partially descheduling cannabis and expanding medical access [6]. Sanity Group has publicly stated it supplies a substantial share of German pharmacy demand for medical cannabis flower and extracts [1][3]. Independent verification of any specific market-share figure (including the often-cited "around 10%") is difficult; these are company-reported numbers, not regulator-published statistics Weak / limited.
In Switzerland, Sanity Group is one of several operators participating in the federally authorised pilot trials of regulated adult-use cannabis sales, which run under Article 8a of the Swiss Narcotics Act [4][7].
The Vaay line covers CBD oils, topicals, and related products sold through e-commerce and retail in several European countries [8]. CBD products in the EU sit in a complex regulatory zone — novel-food status for ingestibles is still being worked out — and category rules vary by member state [9].
Notable products and services
On the medical side, Sanity Group distributes cannabis flower and extracts to German pharmacies, including products sourced from international licensed producers under EU-GMP standards [1][3]. The company has also announced collaborations on clinical research, including studies relating to cannabinoid-based therapies [1].
On the consumer side, Vaay markets CBD oils, sprays, capsules, topical creams, and bath products [8]. This article does not recommend any specific product. CBD content, bioavailability claims, and health-related marketing for CBD products vary widely in accuracy across the European market; see CBD for general context Disputed.
Reputation, awards, and controversies
Sanity Group is frequently cited in German-language business press (Handelsblatt, Manager Magazin, Gründerszene) as a leading domestic cannabis startup [2][3]. The company's founders have been visible advocates for cannabis policy reform in Germany, and executives have participated in industry associations such as the Branchenverband Cannabiswirtschaft (BvCW) [10].
As of the last-checked date, we are not aware of major regulatory enforcement actions against Sanity Group from BfArM, the German federal drug agency, or from Swissmedic. Absence of public actions is not the same as a clean compliance record — it just means nothing notable has been reported No data.
Like most European cannabis companies, Sanity Group has navigated a period of declining valuations and tightening capital markets since 2022, and has reportedly undertaken restructuring and headcount adjustments [3]. Specific financial figures should be treated as point-in-time and verified against current reporting.
Availability and legal-market notes
Medical cannabis products distributed by Sanity Group are available only to patients in Germany with a valid prescription, dispensed through licensed pharmacies [6]. Vaay CBD products are sold through online channels and retail in several European countries; legal status of specific CBD products depends on national rules, THC thresholds, and food/cosmetic categorisation [9].
Under the 2024 German Cannabis Act, non-commercial adult-use possession and home cultivation were partially legalised, and "cannabis social clubs" (Anbauvereinigungen) were introduced, but commercial recreational sales are not generally permitted [6]. Sanity Group's commercial activity in Germany therefore remains primarily medical.
What to verify before relying on brand claims
Before treating any marketing or PR claim from Sanity Group (or its competitors) as fact, check:
- Market share and patient numbers: these are company-reported and not published by German regulators in a comparable form. The "~10% of the German medical market" figure is a company estimate Weak / limited.
- Product sourcing and GMP status: for medical products, ask the dispensing pharmacy for the actual manufacturer and country of origin; Sanity Group acts as distributor for products it does not always cultivate itself.
- CBD health claims: EU and national rules restrict medical claims on CBD products. Treat wellness-style language with skepticism Disputed.
- Ownership changes: the cap table evolves with each funding round. For current ownership, check Organigram's most recent annual filings and German Handelsregister entries.
- Swiss pilot results: the Swiss pilots are research projects, not a permanent legal market. Any "available in Switzerland" framing should be read in that context [7].
Profile last checked: 2025.
Sources
- Reported Sanity Group company website, About / Company pages.
- Reported Gründerszene / Business Insider Deutschland coverage of Sanity Group funding and founders.
- Reported Handelsblatt coverage of the German medical cannabis market and Sanity Group.
- Government Swiss Federal Office of Public Health (BAG/FOPH), Pilot trials with cannabis under Article 8a Narcotics Act.
- Reported Organigram Holdings press release announcing strategic investment in Sanity Group, 2021.
- Government Bundesministerium für Gesundheit (BMG), Cannabisgesetz (CanG) — overview of the 2024 German Cannabis Act.
- Government Swiss Federal Office of Public Health, list of authorised cannabis pilot trials and participating operators.
- Reported Vaay official website, product catalogue.
- Government European Commission, Novel Food Catalogue entry on Cannabidiol (CBD).
- Reported Branchenverband Cannabiswirtschaft (BvCW), member directory and policy positions.
How this page was made
Generation history
Drafting assistance and fact-check automation are used, with a human operator spot-checking on a weekly basis. See how articles are made.